Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience.

Roberto SalvatoriPietro MaffeiSusan M WebbThierry BrueJane LoftusSrinivas Rao ValluriRoy GomezMichael P WajnrajchMaria Fleseriu

Published in: Pituitary (2022)

Overall, patients treated with PEGV had small improvements in PASQ. While IGF-I normalization increased with PEGV treatment, IGF-I control had no effects on PASQ and AcroQoL scores.

Keyphrases

patient reported outcomes
growth hormone
pi k akt
binding protein
combination therapy
replacement therapy
newly diagnosed